Each SSI may have the following impact
9.7 days
Average extended hospital length of stay.30,31
>$20,000 USD
Increase in the cost of hospitalization.30,31
2-11 fold
Increased risk of mortality.30
Myriad has a low rate of device-related complications across a range of complex, acute and chronic wounds
- Myriad-treated wounds with a high risk of infection demonstrated 0% SSI rates in most cases.1-7,11,26
- Low infection and graft loss rates, even in contaminated defects.1-7,11,26
- Facilitates rapid vascularization and tissue fill, typically with a single application.1-7,11,26
Myriad may help reduce the overall cost of care
Enables earlier intervention
Despite the presence of contamination.1-4
Reduces the frequency of NPWT dressing changes
By working synergistically with NPWT.2,3
Minimal complications
Low infection rate and graft loss, even in contaminated defects1-7,11,26
A versatile portfolio for soft tissue repair
Myriad Matrix™
Multiple layers of AROA ECM to enable regeneration of organized, functional tissue.
Myriad Morcells™
A conformable graft of morselized Myriad. Ideal for irregular, tunneled or undermined wounds.
Myriad Morcells Fine™
A finer particulate of Myriad Morcells. Ideal for irregular, tunneled or undermined wounds.
AROA ECM™
Our foundation technology
Derived from ovine forestomach, the AROA ECM technology is a patented platform for our soft tissue repair and reconstruction portfolio. It regenerates functional tissue, enabling clinicians to achieve more for patients.